On January 3rd, Bristol-Myers Squibb announced its agreement to acquire Celgene for approximately $74 billion. This merger is a sign of change for pharmaceutical companies. Like a military planning for the previous war, corporations are always planning for the past rather than the future. In the past, pharmaceutical companies could simply stay big, block market… [Read More]
HIV Cure in the News
Today the world celebrated the second patient cured of HIV. The work of Ravindra Gupta teaches us lessons not only of the potential for an HIV cure in the future, but how that cure may function. While a bone marrow transplant is not a practical way to cure HIV in most patients, the mechanism of… [Read More]
Why Invest in an HIV Gene Therapy Cure?
Research and innovation to cure HIV is developing fast. American Gene Technologies (AGT) is emerging as a leader in the field with their first functional cure for HIV, expected to enter clinical trials in 2019. Unlike the current antiretrovirals used in HIV treatment, AGT’s solution is a one-time intervention that eliminates the need for ongoing… [Read More]
The Next Generation of Gene Therapy Companies
The future of medicine is bright. This year brought several first in class technologies over the finish line. The underpinning of these radical medical developments is the understanding of how human genes can be modified to cure diseases and save lives. The technology which captured the most attention this year is CAR-T therapy. A CAR-T… [Read More]
The Gene Therapy Market is going to produce a Microsoft
The most common analogy used to compare the science of DNA to other industries is that of computer software. DNA can be viewed as a series of commands (genes) that are coded in four nucleotides (represented by A, G, C, and T). Those letters are interpreted by the cellular machinery to produce cell products like… [Read More]
